Does the media prefer EVH or OPRX?

In the previous week, Evolent Health had 3 more articles in the media than OptimizeRx. MarketBeat recorded 4 mentions for Evolent Health and 1 mentions for OptimizeRx. Evolent Health's average media sentiment score of 0.57 beat OptimizeRx's score of 0.00 indicating that Evolent Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolent Health 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to OPRX or AMWL?

In the previous week, American Well had 1 more articles in the media than OptimizeRx. MarketBeat recorded 2 mentions for American Well and 1 mentions for OptimizeRx. American Well's average media sentiment score of 1.08 beat OptimizeRx's score of 0.00 indicating that American Well is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral American Well 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, CCLD or OPRX?

CareCloud has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than CareCloud, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CareCloud $128.64M 0.83 $10.80M $0.07 35.71 OptimizeRx $109.43M 1.32 $5.13M $0.23 33.26

Does the media prefer CCLD or OPRX?

In the previous week, CareCloud had 1 more articles in the media than OptimizeRx. MarketBeat recorded 2 mentions for CareCloud and 1 mentions for OptimizeRx. CareCloud's average media sentiment score of 0.33 beat OptimizeRx's score of 0.00 indicating that CareCloud is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CareCloud 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

OptimizeRx (OPRX) Competitors

$7.65 -0.06 (-0.78%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$7.58 -0.07 (-0.97%)

As of 08:21 AM Eastern

Compare

OPRX vs. EVH, NRC, AMWL, HCAT, and CCLD

Should you buy OptimizeRx stock or one of its competitors? OptimizeRx's main competitors and comparable companies include Evolent Health (EVH), National Research (NRC), American Well (AMWL), Health Catalyst (HCAT), and CareCloud (CCLD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does OptimizeRx compare to Evolent Health?

Evolent Health (NYSE:EVH) and OptimizeRx (NASDAQ:OPRX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Evolent Health currently has a consensus target price of $5.96, suggesting a potential upside of 26.28%. OptimizeRx has a consensus target price of $11.43, suggesting a potential upside of 49.39%. Given OptimizeRx's higher possible upside, analysts plainly believe OptimizeRx is more favorable than Evolent Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolent Health	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Evolent Health had 3 more articles in the media than OptimizeRx. MarketBeat recorded 4 mentions for Evolent Health and 1 mentions for OptimizeRx. Evolent Health's average media sentiment score of 0.57 beat OptimizeRx's score of 0.00 indicating that Evolent Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolent Health	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OptimizeRx has lower revenue, but higher earnings than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolent Health	$2.10B	0.25	-$534.51M	-$4.57	N/A
OptimizeRx	$109.43M	1.32	$5.13M	$0.23	33.26

OptimizeRx has a net margin of 4.66% compared to Evolent Health's net margin of -24.08%. OptimizeRx's return on equity of 9.44% beat Evolent Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolent Health	-24.08%	-4.27%	-1.06%
OptimizeRx	4.66%	9.44%	7.11%

76.5% of OptimizeRx shares are held by institutional investors. 1.5% of Evolent Health shares are held by company insiders. Comparatively, 7.5% of OptimizeRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Evolent Health has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

Summary

OptimizeRx beats Evolent Health on 11 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to National Research?

OptimizeRx (NASDAQ:OPRX) and National Research (NASDAQ:NRC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

National Research has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	1.32	$5.13M	$0.23	33.26
National Research	$137.39M	3.63	$11.60M	$0.25	87.68

In the previous week, OptimizeRx had 1 more articles in the media than National Research. MarketBeat recorded 1 mentions for OptimizeRx and 0 mentions for National Research. OptimizeRx's average media sentiment score of 0.00 beat National Research's score of -1.14 indicating that OptimizeRx is being referred to more favorably in the media.

Company	Overall Sentiment
OptimizeRx	Neutral
National Research	Negative

OptimizeRx has a net margin of 4.66% compared to National Research's net margin of 4.18%. National Research's return on equity of 164.26% beat OptimizeRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	4.66%	9.44%	7.11%
National Research	4.18%	164.26%	14.67%

OptimizeRx has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, National Research has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

OptimizeRx currently has a consensus target price of $11.43, indicating a potential upside of 49.39%. National Research has a consensus target price of $26.00, indicating a potential upside of 18.61%. Given OptimizeRx's stronger consensus rating and higher possible upside, analysts plainly believe OptimizeRx is more favorable than National Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 47.3% of National Research shares are owned by institutional investors. 7.5% of OptimizeRx shares are owned by insiders. Comparatively, 9.2% of National Research shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

OptimizeRx and National Research tied by winning 8 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to American Well?

OptimizeRx (NASDAQ:OPRX) and American Well (NYSE:AMWL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

In the previous week, American Well had 1 more articles in the media than OptimizeRx. MarketBeat recorded 2 mentions for American Well and 1 mentions for OptimizeRx. American Well's average media sentiment score of 1.08 beat OptimizeRx's score of 0.00 indicating that American Well is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
American Well	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 56.1% of American Well shares are owned by institutional investors. 7.5% of OptimizeRx shares are owned by company insiders. Comparatively, 12.8% of American Well shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

OptimizeRx has a net margin of 4.66% compared to American Well's net margin of -35.75%. OptimizeRx's return on equity of 9.44% beat American Well's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	4.66%	9.44%	7.11%
American Well	-35.75%	-30.12%	-22.30%

OptimizeRx has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, American Well has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market.

OptimizeRx presently has a consensus price target of $11.43, indicating a potential upside of 49.39%. American Well has a consensus price target of $9.50, indicating a potential downside of 20.26%. Given OptimizeRx's stronger consensus rating and higher probable upside, analysts clearly believe OptimizeRx is more favorable than American Well.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
American Well	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

OptimizeRx has higher earnings, but lower revenue than American Well. American Well is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	1.32	$5.13M	$0.23	33.26
American Well	$249.32M	0.79	-$95.70M	-$4.77	N/A

Summary

OptimizeRx beats American Well on 11 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to Health Catalyst?

Health Catalyst (NASDAQ:HCAT) and OptimizeRx (NASDAQ:OPRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

OptimizeRx has a net margin of 4.66% compared to Health Catalyst's net margin of -90.61%. OptimizeRx's return on equity of 9.44% beat Health Catalyst's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-90.61%	-1.83%	-0.80%
OptimizeRx	4.66%	9.44%	7.11%

Health Catalyst has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

OptimizeRx has lower revenue, but higher earnings than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Catalyst	$311.14M	0.38	-$177.97M	-$3.68	N/A
OptimizeRx	$109.43M	1.32	$5.13M	$0.23	33.26

Health Catalyst currently has a consensus price target of $2.82, indicating a potential upside of 77.53%. OptimizeRx has a consensus price target of $11.43, indicating a potential upside of 49.39%. Given Health Catalyst's higher possible upside, analysts clearly believe Health Catalyst is more favorable than OptimizeRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.15
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

85.0% of Health Catalyst shares are held by institutional investors. Comparatively, 76.5% of OptimizeRx shares are held by institutional investors. 19.4% of Health Catalyst shares are held by insiders. Comparatively, 7.5% of OptimizeRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, OptimizeRx had 1 more articles in the media than Health Catalyst. MarketBeat recorded 1 mentions for OptimizeRx and 0 mentions for Health Catalyst. Health Catalyst's average media sentiment score of 0.59 beat OptimizeRx's score of 0.00 indicating that Health Catalyst is being referred to more favorably in the media.

Company	Overall Sentiment
Health Catalyst	Positive
OptimizeRx	Neutral

Summary

OptimizeRx beats Health Catalyst on 10 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to CareCloud?

CareCloud (NASDAQ:CCLD) and OptimizeRx (NASDAQ:OPRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

10.2% of CareCloud shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 14.8% of CareCloud shares are owned by insiders. Comparatively, 7.5% of OptimizeRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, CareCloud had 1 more articles in the media than OptimizeRx. MarketBeat recorded 2 mentions for CareCloud and 1 mentions for OptimizeRx. CareCloud's average media sentiment score of 0.33 beat OptimizeRx's score of 0.00 indicating that CareCloud is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CareCloud	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CareCloud has a net margin of 6.21% compared to OptimizeRx's net margin of 4.66%. CareCloud's return on equity of 27.07% beat OptimizeRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CareCloud	6.21%	27.07%	14.56%
OptimizeRx	4.66%	9.44%	7.11%

CareCloud has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than CareCloud, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareCloud	$128.64M	0.83	$10.80M	$0.07	35.71
OptimizeRx	$109.43M	1.32	$5.13M	$0.23	33.26

CareCloud has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

CareCloud currently has a consensus target price of $3.25, indicating a potential upside of 30.00%. OptimizeRx has a consensus target price of $11.43, indicating a potential upside of 49.39%. Given OptimizeRx's stronger consensus rating and higher probable upside, analysts clearly believe OptimizeRx is more favorable than CareCloud.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareCloud	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

CareCloud beats OptimizeRx on 10 of the 16 factors compared between the two stocks.

Get OptimizeRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OPRX vs. The Competition

Export

Metric	OptimizeRx	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$145.23M	$1.72B	$7.36B	$12.81B
Dividend Yield	N/A	4.69%	2.54%	10.78%
P/E Ratio	33.26	21.28	270.59	24.05
Price / Sales	1.32	78.65	643.38	104.95
Price / Cash	7.84	31.69	29.03	36.89
Price / Book	1.11	5.82	11.09	6.40
Net Income	$5.13M	-$18.66M	$3.46B	$347.95M
7 Day Performance	-7.05%	0.88%	1.73%	1.48%
1 Month Performance	22.60%	12.48%	7.34%	5.13%
1 Year Performance	-55.00%	-16.33%	26.13%	17.00%

OptimizeRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OPRX OptimizeRx	3.6887 of 5 stars	$7.65 -0.8%	$11.43 +49.4%	-55.7%	$145.23M	$109.43M	33.26	100
EVH Evolent Health	2.7221 of 5 stars	$4.70 flat	$5.96 +26.9%	-50.7%	$531.38M	$1.88B	N/A	4,200
NRC National Research	2.1333 of 5 stars	$22.05 +1.1%	$26.00 +17.9%	+42.6%	$501.55M	$140.00M	88.20	490	Negative News
AMWL American Well	2.735 of 5 stars	$11.66 -1.1%	$9.50 -18.5%	+66.3%	$193.00M	$218.53M	N/A	1,040	Positive News
HCAT Health Catalyst	3.1539 of 5 stars	$1.57 -3.6%	$2.82 +79.6%	-51.5%	$118.30M	$292.25M	N/A	1,200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OPRX) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OptimizeRx (OPRX) Competitors

OPRX vs. EVH, NRC, AMWL, HCAT, and CCLD

How does OptimizeRx compare to Evolent Health?

Summary

How does OptimizeRx compare to National Research?

Summary

How does OptimizeRx compare to American Well?

Summary

How does OptimizeRx compare to Health Catalyst?

Summary

How does OptimizeRx compare to CareCloud?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPRX vs. The Competition

OptimizeRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OptimizeRx (OPRX) Competitors

OPRX vs. EVH, NRC, AMWL, HCAT, and CCLD

How does OptimizeRx compare to Evolent Health?

Do analysts prefer EVH or OPRX?

Does the media prefer EVH or OPRX?

Which has preferable earnings and valuation, EVH or OPRX?

Is EVH or OPRX more profitable?

Do insiders and institutionals hold more shares of EVH or OPRX?

Which has more volatility and risk, EVH or OPRX?

Summary

How does OptimizeRx compare to National Research?

Which has preferable valuation and earnings, OPRX or NRC?

Does the media refer more to OPRX or NRC?

Is OPRX or NRC more profitable?

Which has more volatility & risk, OPRX or NRC?

Do analysts prefer OPRX or NRC?

Do insiders & institutionals have more ownership in OPRX or NRC?

Summary

How does OptimizeRx compare to American Well?

Does the media refer more to OPRX or AMWL?

Do insiders and institutionals have more ownership in OPRX or AMWL?

Is OPRX or AMWL more profitable?

Which has more risk and volatility, OPRX or AMWL?

Do analysts prefer OPRX or AMWL?

Which has stronger earnings & valuation, OPRX or AMWL?

Summary

How does OptimizeRx compare to Health Catalyst?

Is HCAT or OPRX more profitable?

Which has more volatility & risk, HCAT or OPRX?

Which has stronger earnings and valuation, HCAT or OPRX?

Do analysts rate HCAT or OPRX?

Do institutionals and insiders believe in HCAT or OPRX?

Does the media favor HCAT or OPRX?

Summary

How does OptimizeRx compare to CareCloud?

Do insiders and institutionals have more ownership in CCLD or OPRX?

Does the media prefer CCLD or OPRX?

Is CCLD or OPRX more profitable?

Which has preferable valuation and earnings, CCLD or OPRX?

Which has more risk and volatility, CCLD or OPRX?

Do analysts rate CCLD or OPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPRX vs. The Competition

OptimizeRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools